Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series: World’s leading Event Organizer
As per available reports about 18 relevant Journals, 11 Conferences, 71 National symposiums are presently dedicated exclusively to restenosis and about 54 articles are being published on cardiac Restenosis.
Restenosis means that a section of blocked artery that was opened up with angioplasty or a stent has become narrowed again. There are many treatment options for patients who have restenosis after receiving a stent. The first step in treatment is meeting with an experienced cardiac interventionist (a doctor who performs procedures to open up clogged arteries). The doctor can determine the best type of treatment based on the location of the blocked stent, how badly it is blocked, and information about the patient (such as age, type of cardiovascular disease, and other medical conditions). The doctor will perform a catheterization and can use tests during the procedure to get more information about the blockage by looking inside the artery. These tests include intravascular ultrasound (IVUS) and optical coherence tomography (OCT).
OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.
Scope and importance:
Restenosis literally means the recurrence of stenosis, a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become narrowed. This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ.
Potential restenosis is a common adverse event of endovascular procedures. Procedures frequently used to treat the vascular damage from atherosclerosis and related narrowing and narrowing (restenosis) of blood vessels include vascular surgery, cardiac surgery, and angioplasty. The phenomenon of vessel restenosis, an immune response to damaged tissue, is known to be a common adverse event and the Achilles heel of angioplasty and stenting. Reducing restenosis is one of the highest priorities in research and the development of new endovascular technologies. Restenosis rates of drug-eluting stents appear to be significantly lower than bare-metal stents, and research is underway to determine if drug-eluting balloons also improve restenosis outcomes.
When a stent is used and restenosis occurs, this is called in-stent restenosis or ISR. If it occurs following balloon angioplasty , this is called post-angioplasty restenosis or PARS. The diagnostic threshold for restenosis in both ISR and PARS is ≥50% stenosis. If restenosis occurs after a procedure, follow-up imaging is not the only way to initially detect compromised blood flow. Symptoms may also suggest or signal restenosis, but this should be confirmed by imaging. For instance, a coronary stent patient who develops restenosis may experience recurrent chest pain (angina) or suffer from a minor or major heart attack (myocardial infarction), though they may not report it. This is why it is important that a patient comply with follow-up screenings and the clinician follows through with a thorough clinical assessment. But it is also important to note that not all cases of restenosis lead to clinician symptoms, or be asymptomatic.
Restenosis literally means the ''re''occurrence of ''stenosis'', a narrowing of a blood vessel, leading to restricted blood flow. Restenosis usually pertains to an artery or other large blood vessel that has become narrowed, received treatment to clear the blockage and subsequently become renarrowed. This is usually restenosis of an artery, or other blood vessel, or possibly a vessel within an organ. This term is common in vascular surgery,cardiac surgery, and angioplasty, all branches of medicine that frequently treat narrowing of blood vessels. It can be defined as a reduction in the circumference of the lumen of 50% or more, and had a high incidence rate (25-50%) in patients who had undergone balloon angioplasty, with the majority of patients needing further angioplasty within 6 months.
The Asia/Pacific market for coronary stents is forecasted to grow 6.7% annually over the period from 2008 to 2017. In the United States (U.S.), the total potential market for tissue engineering and cell transplantation technologies for cardiac and vascular indications is expected to exceed $22.8 billion in the year 2019. In U.S., nearly 80% of stents used for coronary procedures are drug-eluting stents. Germany has had the quickest adoption of DES technology. The German market accounts for nearly 50% of the Europe market for DES. In countries such as Spain and Portugal, while the market will show double-digit growth, an extremely low base and high cost of DES (Drug-Eluting Stent) will hinder adoption in favour of cheaper alternatives, such as drug-coated balloons.
Relevant Society and Associations
1. The Society of Thoracic Surgeons
2. National Organization for Rare Disorders, Inc.
3. National Heart Centre Singapore
4. The American Health Information Management Association
5. Association for European Paediatric Cardiology
6. Global Heart Network Foundation
7. Society for Vascular Surgery
8. Canadian Society for Vascular Surgery
9. Society for Cardiothoracic Surgery in Great Britain & Ireland
10. European Association of Percutaneous Cardiovascular Interventions
11. Society for Cardiovascular Angiography and Interventions
12. European Heart Rhythm Association
13. Egyptian Medical Society of Echocardiography
14. Society of Cardiovascular Anaesthesiologists, Chicago
15. AEPC Association for European Paediatric Cardiology
16. Midwest Pediatric Cardiology Society, Inc.
17. Pediatric Congenital Heart Association’s
18. Asia-Pacific Pediatric Cardiac Society
19. Canadian Pediatric Cardiology Association
20. Russian National Congress of Cardiology
21. British Cardiovascular Society
22. The Cardiac Society of Australia and New Zealand
23. European Society of Hypertension
24. European Atherosclerosis Society
25. The Society for Cardiovascular Angiography and Interventions Foundation, USA
1. Abbott Vascular Devices (Division Of Abbott Laboratories)
2. Cordis Corporation (A Johnson & Johnson Company)
3. Table Cordis Corporation (A Johnson & Johnson Company)
4. Guidant Corporation
5. Table Guidant Corporation
7. Medtronic, Inc.
1. W.L. Gore and Associates Inc.
2. St. Jude Medical Inc.
3. Biosense Webste
4. Cardia Inc.
5. LifeTech Scientific
6. Maquet Cardiovascular
8. Occlutech Holding AG and Pfm medical.
9. Vascutek Ltd
10. Union Diagnostic and Clinical Services Plc.
11. Stryker Medical Company
12. GE Medical Equipment
13. Endologix, Inc.
14. Medtronic Inc.
15. Gore Medical Products
16. Medtronic Equipment
17. SonoSite Inc. – US
18. Hitachi Aloka Medical America
19. Cook Medical Incorporated
20. Abiomed, Inc.
21. Johnson & Johnson
22. Biocompatibles UK Limited
23. iCardiac Technologies, Inc.
24. Edwards Lifesciences Corporation
This page will be updated regularly.
This page was last updated on 14th Sep, 2015
1-702-508-5200 Ext:8031, 8041
1-702-508-5200 Ext:8045, 8047
Immunology & Microbiology Conferences
Nursing and Healthcare Conferences
Clinical and Biochemistry Conferences
1-702-508-5200 Ext:8031, 8037
Material Science Conferences
Genetics & Mol Biology Conferences
Media Partners | Advertising